Abstract: The invention relates to subtilisin enzymes which have been modified by mutating a nucleotide sequence (gene) coding for the subtilisin. The modified subtilisin enzymes have enhanced thermal stability.

Abstract: An improved vector for expression in Bacillus brevis having:(1) a nucleotide sequence (a) represented by a general formula MNOACP;(2) a nucleotide sequence (b) located in the downstream of the nucleotide sequence (a) and represented by a general formula QRSWXY;(3) a nucleotide sequence (c) located in the downstream of the nucleotide sequence (b) and acting as a binding site to ribosome in the cell of Bacillus brevis;(4) a nucleotide sequence (d) located in the downstream of the nucleotide sequence (c) and acting as a translation initiation condon in the cell of Bacillus brevis; and(5) a gene directly connected with the nucleotide sequence (d) and to express in the cell of Bacillus brevis;wherein M represents G or T; N represents C, T or A; O represents A, C or T; P represents T or G; Q represents T or A; R represents T or A; S represents T, C or A; W represents A or G; X represents A or C; and Y represents T or G; and furthermore, wherein A represents adenine, C cytosine, G guanine and T thymine.

Abstract: A stable mutant form of creatine amidohydrolase is disclosed. This enzyme is formed via expression of altered DNA, which may be in plasmid form. Also disclosed is a method for determining creatinine using the mutant form.

Abstract: The invention relates to modified subtilisin enzymes which have increased thermal stability. The modified subtilisin enzymes have at least two or more amino acid mutations which confer increased thermal stability. It has been discovered that combining individual stabilizing mutations in subtilisin frequently results in an additive increase in thermal stability. In addition, the invention pertains to cloned mutant genes coding for a subtilisin material having at least two amino acid substitution which has increased thermal stability.

Abstract: The present invention comprises novel recombinant DNA compounds which encode monoclonal antibody KS1/4 and chimeric derivatives of monoclonal antibody KS1/4. Eukaryotic expression vectors have been constructed that comprise novel KS1/4-encoding DNA and drive expression of KS1/4 when transformed into an appropriate host cell. The novel expression vectors can be used to create modified and chimeric derivatives of KS1/4. The recombinant-produced KS1/4, KS1/4 derivatives and KS1/4 chimeras are useful for the diagnosis, prognosis and treatment of disease states including adenocarcinoma.

Abstract: A luciferase gene isolated from Luciola cruciata (Japanese firefly) coding for an amino acid sequence shown in FIG. 4 and a novel recombinant DNA characterized by incorporating a gene coding for luciferase into a vector DNA are disclosed. There is also disclosed a method of producing luciferase which comprises culturing in a medium a microorganism containing a recombinant DNA having inserted a gene coding for luciferase in a vector DNA and belonging to the genus Escherichia capable of producing luciferase and collecting luciferase from the culture.

Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.

Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.

Abstract: A biological reagent and diagnostic system for the detection and quantitation of endothelial plasminogen activator inhibitor (PAI) are disclosed, as are substantially pure, recombinant human endothelial PAI, its biologically pure gene and a vector for cloning the gene and expressing a gene product.

Abstract: A method for altering a cell by exchanging a preselected cellular DNA sequence with an exogenous DNA sequence different from the cellular DNA sequence employs an exogenous DNA sequence encapsidated in a polyoma or polyoma-like capsid. The polyoma capsid is then contacted to the cell so that the exogenous DNA sequence is introduced within the cell and exchanges with the preselected cellular DNA sequence by homologous recombination.A preferred article of manufacture comprises a polyoma capsid and a plurality of DNA sequences encapsulated within the polyoma capsid. The DNA sequences each comprise not more than an incomplete portion of a single preselected gene.The exogenous DNA sequence may optionally be complexed to a DNA binding protein, such as a recA protein, prior to encapsulating the exogenous DNA sequence within a viral capsid, so that the uptake of the DNA sequence into the capsid is enhanced.

Abstract: The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.